Last edition
News about "Gazyva"
Genentech's Gazyva Shows Strong Phase III Results in Primary Membranous Nephropathy
Phase III MAJESTY trial shows Gazyva significantly improves complete remission rates in primary membranous nephropathy, potentially paving the way for the first targeted therapy for the condition.
Gazyva | 17/02/2026 | By News Bureau | 112
Roche's Gazyva/Gazyvaro Shows Positive Results for Systemic Lupus Erythematosus in Phase III trials
The ALLEGORY study met its primary endpoint showing a higher percentage of people achieved a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva/Gazyvaro versus standard therapy.
Gazyva | 05/11/2025 | By Dineshwori | 261
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy